Showing posts with label platform. Show all posts
Showing posts with label platform. Show all posts
5 Oct 2021
Find out more about CCS's senior researchers' expertise
The CCS Research team has updated the school's database of senior researchers (see in the research section of the CCS Intranet). By noting each individual's research techniques and general expertise, this new database aims to provide the following:
8 May 2019
Platform Access Grants Success!
![]() |
| Jess Borger, Tiffany Bouchery and Emily Edwards |
Congratulations to Emily Edwards, Jess Borger and Tiffany Bouchery who recently received Platform Access Grants from the Faculty of Medicine, Nursing and Health Sciences. The scheme is an initiative to encourage research development through engagement with the FMNHS technology research platforms, with a view to strengthen researchers capability and international competitiveness. The seed funding also aims at attracting external national and international competitive grants.
20 Jun 2017
Welcome to Dr Nick Wong!
![]() |
| Dr Nick Wong, new bioinformatics platform contact |
Nick completed his PhD in 2006 with Professor K. H. Andy Choo on DNA methylation of Neocentromeres. His expertise is in DNA methylation profiling (Illumina Infinium, Bisulfite Sequencing, MBD enrichment) on challenging samples; RNA analysis on challenging samples (including RNA-Seq); End-to-end experience for most NGS workflows (sample, library preparation, sequencing, bioinformatic analysis).
13 May 2016
Congratulations to Drs Caroline Gurvich and Kiymet Bozaoglu on their platform grant success
![]() |
| Dr Caroline Gurvich, Research Fellow/ Clinical Neuropsychologist at MAPrc |
27 Apr 2016
Congratulations to Karen Alt, Tiffany Khong and Ioanna Savvidou for Platform Access Grant success!
|
|
|
Multiple Myeloma (MM) is the second most common hematologic malignancy accounting for 13% of hematologic cancers. Despite the introduction of new therapeutic modalities, relapse is inevitable due to the emergence of drug resistance. Thus, it is important to identify and validate new therapeutic agents that target alternative pathways that contribute to the pathogenesis and progression of MM. This new treatment approach will be evaluated by using molecular imaging for monitoring anti-myeloma therapeutic effect in vivo.
Subscribe to:
Posts (Atom)






